DIACEUTICS PLC

Investor Presentation • Jun 16, 2021

National Storage Mechanism | Additional information

RNS Number : 0174C

Diaceutics PLC

16 June 2021

16 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Capital Markets Day and KPI Update

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing will today host a virtual Capital Markets Day ("CMD") for investors and equity analysts, from 1pm BST. 

The event will be led by Group CEO, Peter Keeling, and members of the senior management team and will include a series of presentations, a demonstration of the DXRX SaaS platform, views from an industry expert panel including:

·    Pharmaceutical Partner: a senior executive within one of the world's top five pharmaceutical companies

·    Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan

·    Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant.

In addition, there will be a strategic update from the Company, along with a live Q&A.

A video replay of the presentation will be available via the Group's website post-event.

To register for the DXRX Capital Markets Day or for any further assistance or questions relating to the event, please contact diaceutics@almapr.co.uk

Key Performance Indicator Updates

During the presentation, as part of the strategic update, management will outline an update to a number of the Company's KPIs* demonstrating continued positive progress with the uptake of the DXRX platform and its impact on the Company's financial model:  

·    Over 40% of sales pipeline generation for Q2 is currently represented by DXRX-enabled products on a contract value basis*

·    16% increase in average sales prices per project for Pharma clients in 2021, when compared to the 2020 average contracted price*

·    10% increase in Gross Margin % (excluding amortisation and travel)**

·    14 client projects live on DXRX platform as at end April

·    Six Diagnostic Partners and 10 Pharma partners recruited onto the DXRX platform as at end April; and

·    223 Lab partners recruited onto the DXRX platform as at end April (growing substantially from the position of 101 partners as at end March)

*Key Performance Indicator metrics as of 24 May 2021

**Key performance Indicator metrics as of 30 April 2021

Peter Keeling, CEO and Founder of Diaceutics PLC, commented: "We continue to make excellent progress in the roll out of the DXRX platform, our innovative diagnostic commercialisation platform for precision medicine. We are seeing clear evidence of its value to stakeholders within the Pharma industry and to Diaceutics, providing us with the ability to scale our offering in line with the increased growth in the precision medicine industry.  In just a few months post launch, we have built the foundations for platform adoption at scale, achieving key expansion milestones such as lab onboarding and are confident that we are on the path towards becoming a strategically embedded platform provider to the Pharma industry."

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDGPURCQUPGPUA